The clearance of Tryngolza gives Ionis its first wholly-owned, marketed medicine. Elsewhere, Robert Temple became the latest ...

Novo shares lost nearly a fifth of their value after an experimental combination treatment called cagrisema fell short of the ...

An startup formed by KdT Ventures intends to test the drug, which was once licensed to Merck and evaluated in multiple ...

Nov. 5, 2025 – Nov. 6, 2025 • Dubai, United Arab Emirates ...

DiveWire guarantees visibility for your news announcements through instant distribution to BioPharma Dive’s audience and its 153,500 newsletter subscribers for 21 days.

Namandjé Bumpus, the Food and Drug Administration’s second-in-command, will depart the regulator at the end of the year, according to an email FDA Commissioner Robert Califf sent to agency staff on ...

Doctors could have a new treatment option for protecting newborn infants from respiratory syncytial virus if the Food and Drug Administration approves Merck & Co.’s drug clesrovimab by next summer.

While the results are from a short Phase 2 trial, Sanofi and Teva’s findings suggest duvakitug could be the most potent drug among a handful of closely watched antibody therapies for inflammatory ...

Pfizer on Tuesday said it anticipates bringing in between $61 billion and $64 billion in revenue next year, matching this year’s expected sum and within range of Wall Street forecasts. The ...

BrightInsight, Inc.today announced an expanded multi-year partnership to support Sanofi’s ambition to halve the time from discovery to commercial launch of its future pipeline. Under the terms of ...

Jazz Pharmaceuticals on Monday said it will begin searching for a successor to CEO Bruce Cozadd, who plans to retire from the company he helped start more than two decades ago. Cozadd will stay on as ...

Merck & Co. has long been dominant in cancer immunotherapy, with its drug Keytruda earning 40 approvals en route to becoming the world’s best-selling medicine. But the New Jersey-based drugmaker has ...